Cargando…

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wright, Laura E., Harhash, Ahmed A., Kozlow, Wende M., Waning, David L., Regan, Jenna N., She, Yun, John, Sutha K., Murthy, Sreemala, Niewolna, Maryla, Marks, Andrew R., Mohammad, Khalid S., Guise, Theresa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352410/ https://www.ncbi.nlm.nih.gov/pubmed/28039445 http://dx.doi.org/10.18632/oncotarget.14139

Ejemplares similares

Excess TGF-β mediates muscle weakness associated with bone metastases in mice
por: Waning, David L., et al.
Publicado: (2015)

Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model
por: Regan, Jenna N., et al.
Publicado: (2017)

Role of TGF-β in breast cancer bone metastases
por: Chiechi, Antonella, et al.
Publicado: (2013)

The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm
por: Trivedi, Trupti, et al.
Publicado: (2017)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment
por: Dunn, Lauren K., et al.
Publicado: (2009)

Aromatase Activity and Bone Loss in Men
por: Merlotti, Daniela, et al.
Publicado: (2011)

Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis
por: Siclari, Valerie A, et al.
Publicado: (2014)

Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
por: Kwan, Marilyn L., et al.
Publicado: (2014)

Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia
por: Hain, Brian A., et al.
Publicado: (2019)

Regulation of Postnatal Trabecular Bone Formation by the Osteoblast Endothelin A Receptor
por: Clines, Gregory A, et al.
Publicado: (2011)

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis
por: Juárez, Patricia, et al.
Publicado: (2017)

The Aromatase–Estrogen System in the Testes of Non-Mammalian Vertebrates
por: Rosati, Luigi, et al.
Publicado: (2021)

Aromatase expression and role of estrogens in male gonad : a review
por: Carreau, Serge, et al.
Publicado: (2003)

The Role of TGF-β in Bone Metastases
por: Trivedi, Trupti, et al.
Publicado: (2021)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Effects of Estrogens on Adipokines and Glucose Homeostasis in Female Aromatase Knockout Mice
por: Van Sinderen, Michelle L., et al.
Publicado: (2015)

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
por: Zhang, Chao, et al.
Publicado: (2020)

Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells (Review)
por: Liu, Ting, et al.
Publicado: (2021)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Site-Specific Regulation of Sulfatase and Aromatase Pathways for Estrogen Production in Endometriosis
por: Da Costa, Katiane de Almeida, et al.
Publicado: (2022)

ACTH-Producing Thymic Carcinoid: A Rare Cause of Cushing’s Syndrome
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

Aromatase inhibitor treatment for breast cancer: short-term effect on bone health
por: Erbağ, Gökhan, et al.
Publicado: (2015)

X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor
por: Felipe Queiroz, João, et al.
Publicado: (2023)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Articular cartilage chondrocytes express aromatase and use enzymes involved in estrogen metabolism
por: Schicht, Martin, et al.
Publicado: (2014)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
por: Miller, Christopher A., et al.
Publicado: (2016)

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome
por: Grindstad, Thea, et al.
Publicado: (2016)

Assessment of Five Pesticides as Endocrine-Disrupting Chemicals: Effects on Estrogen Receptors and Aromatase
por: Gea, Marta, et al.
Publicado: (2022)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss
por: Chu, Meiling, et al.
Publicado: (2023)

Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
por: Nunes, Frederico Arthur Pereira, et al.
Publicado: (2021)

Loss of REDD1 prevents chemotherapy‐induced muscle atrophy and weakness in mice
por: Hain, Brian A., et al.
Publicado: (2021)

Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
por: Markopoulos, Christos
Publicado: (2010)

The bone–muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health
por: Ballinger, Tarah J., et al.
Publicado: (2022)

NO/GMP as mediators of estrogen effects in bone
por: Kalyanaraman, Hema, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ibm5ul16m606od81ot72g4a8dt